Watch the lively discussion on the future of biosimilars in the U.S., especially as the FDA prepares for another round of public hearings. Panelists addressed the attitudes of current biologic prescribers, key considerations for biosimilars adoption, such as pricing of approved biosimilars, and potential pricing and market barriers to biosimilars acceptance.
The webinar focused on questions of:
- Interchangeability rules
- When should clinicians switch from branded biologics to a biosimilar
- What are the real price savings for patients
- The role of payors in biosimilar adoption
Contact us if you would also like a full copy of our syndicated survey report!
